Canaccord Genuity Maintains Buy on Insulet, Lowers Price Target to $179

Benzinga Newsdesk www.benzinga.com Negative 81.6%

Neg 81.6% Neu 0% Pos 0%

Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $249 to $179.